Literature DB >> 18506663

Staging of non-small cell lung cancer.

Lynn T Tanoue1.   

Abstract

Accurate clinical staging is critical in the evaluation of any patient with non-small cell lung cancer (NSCLC). Staging for NSCLC is based on the tumor, node, metastasis (TNM) system used for most solid tumors. The clinical stage, as determined by all available clinical, radiographic, and biopsy data, provides patients and physicians with an overall assessment of disease extent and prediction of survival and enables the identification of appropriate therapies. It is thus imperative that staging be performed as accurately and comprehensively as possible while also maintaining efficiency. To do so requires an understanding of the staging system, the clinical clues that drive the staging evaluation, and a working knowledge of available noninvasive and invasive diagnostic modalities.

Entities:  

Mesh:

Year:  2008        PMID: 18506663     DOI: 10.1055/s-2008-1076745

Source DB:  PubMed          Journal:  Semin Respir Crit Care Med        ISSN: 1069-3424            Impact factor:   3.119


  10 in total

Review 1.  Gene expression-based prognostic signatures in lung cancer: ready for clinical use?

Authors:  Jyothi Subramanian; Richard Simon
Journal:  J Natl Cancer Inst       Date:  2010-03-16       Impact factor: 13.506

Review 2.  What should physicians look for in evaluating prognostic gene-expression signatures?

Authors:  Jyothi Subramanian; Richard Simon
Journal:  Nat Rev Clin Oncol       Date:  2010-04-27       Impact factor: 66.675

Review 3.  Current status of research and treatment for non-small cell lung cancer in never-smoking females.

Authors:  Shin Saito; Fernando Espinoza-Mercado; Hui Liu; Naohiro Sata; Xiaojiang Cui; Harmik J Soukiasian
Journal:  Cancer Biol Ther       Date:  2017-05-11       Impact factor: 4.742

4.  A five-gene and corresponding protein signature for stage-I lung adenocarcinoma prognosis.

Authors:  Humam Kadara; Carmen Behrens; Ping Yuan; Luisa Solis; Diane Liu; Xuemin Gu; John D Minna; J Jack Lee; Edward Kim; Waun-Ki Hong; Ignacio I Wistuba; Reuben Lotan
Journal:  Clin Cancer Res       Date:  2010-12-16       Impact factor: 12.531

Review 5.  Comprehensive evaluation of published gene expression prognostic signatures for biomarker-based lung cancer clinical studies.

Authors:  H Tang; S Wang; G Xiao; J Schiller; V Papadimitrakopoulou; J Minna; I I Wistuba; Y Xie
Journal:  Ann Oncol       Date:  2017-04-01       Impact factor: 32.976

Review 6.  C4.4A as a biomarker in pulmonary adenocarcinoma and squamous cell carcinoma.

Authors:  Benedikte Jacobsen; Mette Camilla Kriegbaum; Eric Santoni-Rugiu; Michael Ploug
Journal:  World J Clin Oncol       Date:  2014-10-10

7.  Targeted next-generation sequencing reveals recurrence-associated genomic alterations in early-stage non-small cell lung cancer.

Authors:  William C S Cho; Kien Thiam Tan; Victor W S Ma; Jacky Y C Li; Roger K C Ngan; Wah Cheuk; Timothy T C Yip; Yi-Ting Yang; Shu-Jen Chen
Journal:  Oncotarget       Date:  2018-11-20

8.  Combined prognostic value of the SUVmax derived from FDG-PET and the lymphocyte-monocyte ratio in patients with stage IIIB-IV non-small cell lung cancer receiving chemotherapy.

Authors:  Kewei Zhao; Chunsheng Wang; Fang Shi; Yong Huang; Li Ma; Minghuan Li; Yipeng Song
Journal:  BMC Cancer       Date:  2021-01-14       Impact factor: 4.430

Review 9.  Practical approach to linear EUS examination of the mediastinum.

Authors:  Hussein Hassan Okasha; Ahmed El-Meligui; Katarzyna M Pawlak; Michał Żorniak; Hassan Atalla; Amr Abou-Elmagd; Sameh Abou-Elenen; Ramy El-Husseiny; Ahmed Alzamzamy
Journal:  Endosc Ultrasound       Date:  2021 Nov-Dec       Impact factor: 5.628

10.  Circ_MDM2_000139, Circ_ATF2_001418, Circ_CDC25C_002079, and Circ_BIRC6_001271 Are Involved in the Functions of XAV939 in Non-Small Cell Lung Cancer.

Authors:  Haixiang Yu; Lei Xu; Zhengjia Liu; Bo Guo; Zhifeng Han; Hua Xin
Journal:  Can Respir J       Date:  2019-11-27       Impact factor: 2.409

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.